Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
780 | DDR1 | Dong_P3 | Human | Prostate | Tumor | 1.73e-18 | 2.65e-01 | 0.0278 |
780 | DDR1 | Dong_P4 | Human | Prostate | Tumor | 2.80e-09 | 2.14e-01 | 0.0292 |
780 | DDR1 | Dong_P5 | Human | Prostate | Tumor | 1.23e-25 | 2.16e-02 | 0.053 |
780 | DDR1 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 8.34e-03 | 4.12e-01 | 0.1557 |
780 | DDR1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.38e-04 | 4.88e-01 | 0.1633 |
780 | DDR1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 3.98e-04 | 4.10e-01 | 0.1608 |
780 | DDR1 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 4.00e-02 | 4.29e-01 | 0.1604 |
780 | DDR1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 8.43e-05 | 5.06e-01 | 0.1621 |
780 | DDR1 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.30e-02 | 4.22e-01 | 0.1619 |
780 | DDR1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 2.69e-09 | 6.00e-01 | 0.1602 |
780 | DDR1 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 1.40e-03 | 5.55e-01 | 0.1608 |
780 | DDR1 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 3.98e-05 | 7.70e-01 | 0.1622 |
780 | DDR1 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.01e-15 | 6.70e-01 | 0.1575 |
780 | DDR1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 4.40e-07 | 1.79e-01 | 0.1545 |
780 | DDR1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 4.73e-09 | 4.36e-01 | 0.1569 |
780 | DDR1 | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 3.54e-04 | 5.14e-01 | 0.1532 |
780 | DDR1 | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 9.60e-04 | 4.61e-01 | 0.1541 |
780 | DDR1 | P1_S1_AK | Human | Skin | AK | 1.30e-04 | 2.66e-01 | -0.3399 |
780 | DDR1 | P2_S3_AK | Human | Skin | AK | 2.70e-02 | 2.03e-01 | -0.3287 |
780 | DDR1 | P4_S8_cSCC | Human | Skin | cSCC | 8.51e-09 | 2.54e-01 | -0.3095 |
Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DDR1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DDR1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DDR1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DDR1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DDR1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DDR1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DDR1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DDR1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
GO:0010810 | Colorectum | AD | regulation of cell-substrate adhesion | 81/3918 | 221/18723 | 4.80e-08 | 2.55e-06 | 81 |
GO:0031589 | Colorectum | AD | cell-substrate adhesion | 116/3918 | 363/18723 | 4.68e-07 | 1.76e-05 | 116 |
GO:0030879 | Colorectum | AD | mammary gland development | 53/3918 | 137/18723 | 1.46e-06 | 4.58e-05 | 53 |
GO:0001952 | Colorectum | AD | regulation of cell-matrix adhesion | 50/3918 | 128/18723 | 2.05e-06 | 6.05e-05 | 50 |
GO:0042060 | Colorectum | AD | wound healing | 128/3918 | 422/18723 | 2.73e-06 | 7.89e-05 | 128 |
GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0007160 | Colorectum | AD | cell-matrix adhesion | 75/3918 | 233/18723 | 3.56e-05 | 6.45e-04 | 75 |
GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
GO:0061180 | Colorectum | AD | mammary gland epithelium development | 28/3918 | 67/18723 | 8.74e-05 | 1.35e-03 | 28 |
GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
GO:0022612 | Colorectum | AD | gland morphogenesis | 42/3918 | 118/18723 | 1.62e-04 | 2.23e-03 | 42 |
GO:0050878 | Colorectum | AD | regulation of body fluid levels | 108/3918 | 379/18723 | 2.54e-04 | 3.20e-03 | 108 |
GO:0060562 | Colorectum | AD | epithelial tube morphogenesis | 93/3918 | 325/18723 | 5.65e-04 | 6.00e-03 | 93 |
GO:0007589 | Colorectum | AD | body fluid secretion | 33/3918 | 93/18723 | 8.26e-04 | 8.13e-03 | 33 |
GO:0060443 | Colorectum | AD | mammary gland morphogenesis | 18/3918 | 43/18723 | 1.51e-03 | 1.27e-02 | 18 |
GO:0048588 | Colorectum | AD | developmental cell growth | 67/3918 | 234/18723 | 3.03e-03 | 2.25e-02 | 67 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDR1 | SNV | Missense_Mutation | | c.1852N>C | p.Glu618Gln | p.E618Q | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
DDR1 | SNV | Missense_Mutation | rs527938479 | c.1826N>A | p.Arg609Gln | p.R609Q | Q08345 | protein_coding | tolerated(0.69) | benign(0.019) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DDR1 | SNV | Missense_Mutation | novel | c.1438G>A | p.Glu480Lys | p.E480K | Q08345 | protein_coding | tolerated(0.82) | benign(0.291) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDR1 | SNV | Missense_Mutation | rs370113205 | c.1696N>A | p.Val566Ile | p.V566I | Q08345 | protein_coding | tolerated(0.06) | probably_damaging(0.964) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
DDR1 | SNV | Missense_Mutation | novel | c.571C>T | p.Leu191Phe | p.L191F | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DDR1 | deletion | Frame_Shift_Del | novel | c.949delN | p.Met318CysfsTer5 | p.M318Cfs*5 | Q08345 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
DDR1 | SNV | Missense_Mutation | rs557271556 | c.586G>A | p.Ala196Thr | p.A196T | Q08345 | protein_coding | tolerated(0.09) | benign(0.192) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | rs370297461 | c.2282G>A | p.Arg761His | p.R761H | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | novel | c.2569G>A | p.Glu857Lys | p.E857K | Q08345 | protein_coding | deleterious(0) | possibly_damaging(0.699) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | rs776556090 | c.2648N>T | p.Pro883Leu | p.P883L | Q08345 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 381118865 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | US9567304, Compound N-9 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | VAPBGCRAUJRZPO-UHFFFAOYSA-N | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | BDBM50080408 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | US9695118, 4 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | NG7 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 328083456 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102314 | IMATINIB | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 252827391 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 363894135 | MERESTINIB | |